II - In-house lobbyists and trade/business/professional associations
Companies & groups
Kendall Street, 500
Cambridge MA 02142
(+1)617 252 7500
rue de la science 14
Mr David Meeker
Executive Vice President and Head of Sanofi Genzyme
Ms Vinciane Pirard
Sr Director Public Affairs
Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, multiple sclerosis, immunology, and oncology. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world.
rare disease policies, pharmaceutical dossiers and use of biotechnology in health care
in particular in the context of and related to:
- REGULATION (EC) No 141/2000 of 16 December 1999 on orphan medicinal products
- COMMUNICATION FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT, THE COUNCIL, THE EUROPEAN ECONOMIC AND SOCIAL COMMITTEE AND THE COMMITTEE OF THE REGIONS on Rare Diseases: Europe's challenges - Brussels, 11.11.2008 COM(2008) 679 final
- EU Net HTA Joint action
- RD Action Joint Action
Expert Group on Rare diseases
To facilitate access to treatments for high, unmet medical need especially rare genetic diseases and multiple sclerosis.
To support all aspects supporting Europe’s Innovation and Research & Development activities in healthcare.
50%: 1 25%: 2
|No accredited persons|
Member of BIO (US), PhARMA (US), EFPIA (EU), EBE (EU) & EuropaBio (EU)
01/2016 - 12/2016
400,000 € - 499,999 €
No funding received from the EU institutions during the last closed financial year.
By its registration the organisation has signed the Transparency Register Code of Conduct.